Prevalence and economic consequences of medication adherence in diabetes: A systematic literature review

Managed Care Interface

Volumn 19, Issue 7, 2006, Pages 31-41

  Lee, Won Chan ^a   Balu, Sanjeev ^a   Cobden, David ^b   Joshi, Ashish V ^b   Pashos, Chris L ^a  

^a ABT ASSOCIATES   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CLINICAL TRIAL; COMORBIDITY; DIABETES CONTROL; DIABETES MELLITUS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; MEDICAID; MEDICAL SPECIALIST; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACY; POLYPHARMACY; PRESCRIPTION; PRIMARY MEDICAL CARE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

DIABETES MELLITUS; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 33746640915     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Total prevalence of diabetes in the United States, All ages, 2005. National Diabetes Statistics, (diabetes.niddk.nih.gov/dm/pubs/statistics/#7), March 2006.
2. Hogan P, Dall T, Nikolov P, et al: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932.
3. Brown JB, Pedula KL, Bakst AW: The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-1880.
4. Menzin J, Langley-Hawthorne C, Friedman M, et al: Potential short-term economic benefits of improved glycemic control: A managed care perspective. Diabetes Care 2001;24:51-55.
5. Wagner EH, Sandhu N, Newton KM, et al: Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-189.
6. Gray A, Clarke P, Farmer A, et al: United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
7. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
8. Harris MI, Flegal KM, Cowie CC, et al: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey (NHANES) 1988-1994. Diabetes Care 1998;21:518-524.
9. Dailey G, Kim MS, Lian JF: Patient compliance and persistence with antihyperglycemic drug regimens: Evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001;23:1311-1320.
10. Morris AD, Boyle DI, McMahon AD, et al: Adherence to insulin treatment, glycemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Lancet 1997;350:1505-1510.
11. Rajagopalan R, Joyce A, Ollendorf D, et al: Medication compliance in type 2 diabetes patients: Retrospective data analysis (Abstract). Value Health 2003;6:328.
12. Evans JM, Donnan PT, Morris AD: Adherence to oral hypoglycemic agents prior to insulin therapy in type 2 diabetes. Diabet Med 2002;19:685-688.
13. Boccuzzi SJ, Wogen J, Fox J, et al: Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24:1411-1415.
14. Schectman JM, Nadkarni MM, Voss JD: The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015-1021.
15. Dezii CM, Kawabata H, Tran M: Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68-71.
16. Donnan PT, MacDonald TM, Morris AD: Adherence to prescribed oral hypoglycemic medication in a population of patients with type 2 diabetes: A retrospective cohort study. Diabet Med 2002;19:279-284.
17. Winkler A, Teuscher AU, Mueller B, et al: Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly 2002; 132):379-385.
18. Guillausseau PJ: Influence of oral antidiabetic agents in type 2 diabetes: A survey in general practice. Diabetes Metab 2003;29:79-82.
19. Melikian C, White J, Vanderplas A, et al: Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-467.
20. Hertz RP, Unger AN, Lustik MB: Adherence with pharmacotherapy for type 2 diabetes: A retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005;27:1064-1073.
21. Brown JB, Nichols GA, Glauber HS, et al: Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type-2 diabetes mellitus. Clin Ther 1999;21:1045-1057.
22. Lau DT, Nau DP: Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-2153.
23. White TJ, Vanderplas A, Chang E, et al: The costs of nonadherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Disease Management and Health Outcomes 2004;12:181-188.
24. Hepke KL, Martus MT, Share DA: Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144-151.
25. Sokol MC, McGuigan KA, Verbrugge RR, et al: Impact of medication adherence on hospitalization risk and health care cost. Med Care 2005;43:521-530.
26. Balkrishnan R, Rajagopalan R, Shenolikar RA, et al: Health care costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: A retrospective data analysis. Curr Med Res Opin 2004;20:1633-1640.
27. Balkrishnan R, Rajagopalan R, Camacho FT, et al: Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 2003;25:2958-2971.
28. Piette JD, Wagner TH, Potter MB, et al: Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004;42:102-9.
29. Roblin DW, Platt R, Goodman MJ, et al: Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: How much is too much? Med Care 2005;43:951-959.
30. Babazono A, Miyazaki M, Imatoh T, et al: Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the employed health insurance system. Int J Technol Assess Health Care 2005;21:228-233.
31. Goldman DP, Joyce GF, Escarce JJ, et al: Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291:2344-2350.
32. Tamblyn R, Laprise R, Hanley JA, et al: Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-429.
33. Motheral B, Fairman KA: Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001;39:1293-1304.
34. Bowker SL, Mitchell CG, Majumdar SR, et al: Lack of insurance coverage for testing supplies is associated with poorer glycemic control in patients with type 2 diabetes. CMAJ 2004;171:39-43.
35. Cramer JA: A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-1224.
36. DiMatteo MRP: Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Medical Care 2004;42:200-209.
37. Marre M: Before oral agents fail: The case for starting insulin early. Int J Obes 2002;26(Suppl 3):25-30.
38. Owens DR, Zinman B. Bolli GB: Insulins today and beyond. Lancet 2001;358:739-746.
39. Dunbar-Jacob J, Mortimer-Stephens MK: Treatment adherence in chronic disease. J Clin Epidemiol 2001;54(suppl 1):57-60.
40. Haynes RB, McDonald H, Garg AX, et al: Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002;2:CD000011.
41. Roter DL, Hall JA. Merisca R. et al: Effectiveness of interventions to improve patient compliance: A meta-analysis. Med Care 1998;36:1138-1161.
42. Nichols GA, Hillier TA, Javor K, et al: Predictors of glycemic control in insulin-using adults with type 2 diabetes. Diabetes Care 2000;23:273-277.
43. Zambanini A, Newson RB, Maisey M, et al: Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-246.
44. Glasgow RE: Compliance to diabetes regimens: Conceptualization, complexity, and determinants, in Cramer JA, Spilker B, (eds): Patient Compliance in Medical Practice and Clinical Trials. New York, Raven Press, 1991:209-224.
45. Anderson EA. Usher JA: Understanding and enhancing adherence with medications for diabetes. Curr Diab Rep 2003;3:141-148.
46. Raz I, Stranks S. Filipczak R, et al: Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: An 18-week, randomized, open-label study. Clin Ther 2005;27:1432-1443.
47. Rolla AR, Rakel RE: Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005;27:1113-1125.
48. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
49. Testa MA, Simonson DC: Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial. JAMA 1998;280:1490-1496.
50. Korytkowski M, Bell D, Jacobsen C, et al: A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848.
51. Rubin RR, Peyrot M: Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004;27:2495-2497.
52. National diabetes fact sheet, 2005. Centers for Disease Control and Prevention (www.cdc.gov/diabetes), January 2006.